Latest Prednisone Stories
HORSHAM, Pa., May 25, 2011 /PRNewswire/ -- A study titled "Abiraterone and Increased Survival in Metastatic Prostate Cancer," published in the May 26 issue of NEJM, found that patients with metastatic castration-resistant prostate cancer who have received prior chemotherapy containing docetaxel showed a significant improvement in overall survival when treated with ZYTIGA(TM) (abiraterone acetate) plus prednisone compared to patients treated with prednisone plus placebo.
HORSHAM, Pa., April 28, 2011 /PRNewswire/ -- Centocor Ortho Biotech Inc. announced today that the U.S.
SILVER SPRING, Md., April 28, 2011 /PRNewswire-USNewswire/ -- The U.S.
RARITAN, N.J., Oct.
BRIDGEWATER, N.J., Oct. 1 /PRNewswire-FirstCall/ -- Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced today that data from the Phase III TROPIC study, which was the basis for the June 2010 U.S.
Randomized Phase 2 Study of Docetaxel and Prednisone With or Without OGX-011 in Patients With Metastatic Castration-Resistant Prostate Cancer. Chi K.N., et al. JCO Sep 20, 2010: 4247-4254 BOTHELL, WA and VANCOUVER, Sept. 22 /PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals, Inc.
$11 Million Supports Five-Year Study to Compare Treatments ROCHESTER, N.Y., Sept.
NORTHBROOK, Ill., July 23 /PRNewswire/ -- Horizon Pharma, Inc.
PARIS, June 17 /PRNewswire-FirstCall/ -- Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced today that the U.S.
NORTHBROOK, Ill., June 16 /PRNewswire/ -- Horizon Pharma, Inc., announced today that data from the Phase 3 U.S.
- A poem in which the author retracts something said in an earlier poem.